A detailed history of R Squared LTD transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, R Squared LTD holds 2,320 shares of TRVI stock, worth $8,769. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,320
Holding current value
$8,769
% of portfolio
0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 22, 2025

BUY
$2.53 - $4.5 $5,869 - $10,440
2,320 New
2,320 $9.56 Million

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $220M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track R Squared LTD Portfolio

Follow R Squared LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of R Squared LTD, based on Form 13F filings with the SEC.

News

Stay updated on R Squared LTD with notifications on news.